Xencor (XNCR) Gains from Sales and Divestitures (2019 - 2022)
Xencor (XNCR) reported Gains from Sales and Divestitures of $170295.0 for Q3 2022, up 26.51% year-over-year from $134615.0 in Q3 2021, and up 11.37% quarter-over-quarter from $152908.0 in Q2 2022.
Xencor (XNCR) Gains from Sales and Divestitures (2019 - 2022) Analysis & Trends
Xencor (XNCR) has 4 years of Gains from Sales and Divestitures data on file, last reported at $170295.0 in Q3 2022.
- Gains from Sales and Divestitures for Q3 2022 came in at $170295.0, up 26.51% year-over-year; the trailing twelve-month figure through Sep 2022 was $170295.0 (up 26.51% YoY), and the FY2021 annual result was $151555.0, up 143.05% from the prior year.
- Gains from Sales and Divestitures advanced to $170295.0 in Q3 2022 per XNCR's latest filing, from $152908.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $170295.0 in Q3 2022 and troughed at $2502.0 in Q1 2019.
- A 4-year average of $78436.0 and a median of $62355.0 in 2020 frame the typical range for Gains from Sales and Divestitures.
- The sharpest annual moves came in 2020 and 2022: Gains from Sales and Divestitures jumped 660.27% in 2020, then rose 16.4% in 2022.
- A 4-year view of Gains from Sales and Divestitures shows it stood at $11311.0 in 2019, then soared by 451.28% to $62355.0 in 2020, then surged by 143.05% to $151555.0 in 2021, then rose by 12.37% to $170295.0 in 2022.
- Business Quant data shows XNCR's Gains from Sales and Divestitures at $170295.0 in Q3 2022, $152908.0 in Q2 2022, and $137134.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 170,295.00 |
| Sep 30, 2022 | 170,295.00 |
| Jun 30, 2022 | 152,908.00 |
| Jun 30, 2022 | 152,908.00 |
| Mar 31, 2022 | 137,134.00 |
| Mar 31, 2022 | 137,134.00 |
| Dec 31, 2021 | 151,555.00 |
| Dec 31, 2021 | 151,555.00 |
| Sep 30, 2021 | 134,615.00 |
| Sep 30, 2021 | 134,615.00 |
| Jun 30, 2021 | 127,998.00 |
| Jun 30, 2021 | 127,998.00 |
| Mar 31, 2021 | 117,808.00 |
| Mar 31, 2021 | 117,808.00 |
| Dec 31, 2020 | 62,355.00 |
| Dec 31, 2020 | 62,355.00 |
| Sep 30, 2020 | 51,722.00 |
| Sep 30, 2020 | 51,722.00 |
| Jun 30, 2020 | 21,822.00 |
| Jun 30, 2020 | 21,822.00 |